Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-QUT is a nanoparticle-encapsulated formulation of the bioactive flavonoid quercetin, utilizing a poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) polymer matrix for drug delivery. Quercetin is a naturally occurring polyphenolic compound known for its antioxidant, anti-inflammatory, and antineoplastic properties; however, its clinical application is often hindered by poor aqueous solubility, low bioavailability, and rapid systemic clearance. Nano-QUT is designed to overcome these limitations by providing a sustained-release delivery system that enhances cellular uptake and specific tissue distribution. Developed for the treatment of oral malignancies such as tongue squamous cell carcinoma (TSCC), Nano-QUT aims to improve the induction of apoptosis and inhibition of tumor cell proliferation compared to free quercetin by modulating key oncogenic signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nano-QUT.